KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Shares Issued (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Shares Issued data on record, last reported at -$1.0 million in Q4 2025.

  • For Q4 2025, Shares Issued rose 92.54% year-over-year to -$1.0 million; the TTM value through Sep 2025 reached -$12.4 million, down 160.49%, while the annual FY2023 figure was $8.4 million, N/A changed from the prior year.
  • Shares Issued reached -$1.0 million in Q4 2025 per EBS's latest filing, down from $200000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $12.7 million in Q3 2024 and bottomed at -$13.4 million in Q4 2024.
  • Average Shares Issued over 5 years is $1.4 million, with a median of $700000.0 recorded in 2024.
  • Peak YoY movement for Shares Issued: surged 336.67% in 2023, then plummeted 288.73% in 2024.
  • A 5-year view of Shares Issued shows it stood at $3.4 million in 2021, then tumbled by 188.24% to -$3.0 million in 2022, then skyrocketed by 336.67% to $7.1 million in 2023, then tumbled by 288.73% to -$13.4 million in 2024, then surged by 92.54% to -$1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were -$1.0 million in Q4 2025, $200000.0 in Q3 2025, and $700000.0 in Q2 2025.